missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Anthrax Protective Antigen Synthetic Peptide
Description
Anthrax Protective Antigen Synthetic Peptide, PEP-0210, from Invitrogen.
Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm. These toxins are usually sufficient to cause rapid cell death, and often the death of the organism.
Specifications
Specifications
| Species | Bacteria |
| Purification Method | purified |
| Common Name | Anthrax Protective Antigen |
| Concentration | 200 μg/mL |
| Content And Storage | -20°C |
| Description | Synthetic Peptide |
| Format | Liquid |
| Formulation | PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2 |
| For Use With (Application) | Blocking Assay, Control |
| Lyophilized | No |
| Show More |